Rinozine

Quick links

Choose a section

Quick links to important sections

Advertisements

Rinozine

Advertisements
Advertisements

Overview of Rinozine

Quick Facts

Property Description
Active ingredient Cetirizine Hydrochloride
Form Tablet, Capsule, Syrup, Oral Solution
Pharmacological class Selective H1-receptor antagonist
Common use Relief of acute allergy symptoms
Origin Synthetic (Piperazine derivative)

Rinozine: Definition and Pharmacological Classification

Rinozine is a synthetic pharmaceutical preparation containing the active ingredient Cetirizine Hydrochloride, which is classified as a second-generation antihistamine. This medicine functions as a highly specific selective H1-receptor antagonist, acting primarily to modulate the body's allergic response. The compound is a key metabolite of the older antihistamine Hydroxyzine and belongs to the piperazine derivative class. The efficacy and safety profile of second-generation agents are clinically recognized for their robust ability to manage symptoms such as sneezing and pruritus, often with a minimized potential for sedation compared to earlier drugs.

Composition and Available Forms

The therapeutic action of Rinozine is delivered entirely by the Cetirizine Hydrochloride active ingredient, making it a single-ingredient product (monotherapy). This ingredient is formulated into various dosage forms for the oral route of administration, which commonly include the tablet, capsule, and liquid preparations such as the syrup and oral solution. The liquid forms ensure the medicine can be reliably administered across different patient groups; for instance, the syrup is often utilized to accommodate children who benefit from its liquid presentation.

General Purpose and Targeted Action

The general purpose of Rinozine is the efficient management and relief of acute allergy symptoms through targeted pharmacological intervention. The drug's classification as an H1-receptor antagonist means it effectively blocks the action of histamine, the natural chemical mediator responsible for triggering the inflammatory cascade and physical manifestations of an allergic reaction. Official labeling confirms the drug's role in providing relief from both seasonal and perennial allergic rhinitis. This high degree of selectivity confirms the medicine's designed utility in suppressing the biological activity that initiates common allergic discomforts experienced during a typical pollen season.

Regulatory References

  1. Cetirizine - StatPearls - NCBI Bookshelf
  2. Label: CETIRIZINE HYDROCHLORIDE tablet, film coated - DailyMed - NIH
Advertisements

What side effects are possible with Rinozine?

Possible side effects and safety information

The safety profile of Rinozine (Cetirizine Hydrochloride) is officially documented according to standardized regulatory classifications, grouping potential adverse reactions by both frequency and the specific system of the body affected.

Adverse Reactions Classified by Frequency

Official labeling classifies adverse reactions into defined tiers based on reported incidence. The most common (≥ 1/100 to <1/10) side effects typically involve the nervous system and gastrointestinal tract, including somnolence, fatigue, headache, dizziness, and dry mouth.

Less frequently reported (uncommon, rare, or very rare) reactions cover a wider range of systems. Reactions classified as rare (≥ 1/10,000 to <1/1,000) include hypersensitivity reactions, convulsions, and documented instances of hepatic function abnormal (e.g., elevated liver enzymes).

Serious Adverse Reactions and Systemic Effects

Adverse reactions that are serious, though often very rare (<1/10,000), include severe allergic responses such as anaphylactic shock and angioneurotic oedema (swelling). Other systems involved in less frequent reactions include the skin (pruritus, rash, urticaria) and the urinary system (dysuria, urinary retention).

Population-Specific Safety Statements

Specific safety considerations are noted for certain patient populations. For individuals with renal impairment, a reduction in drug clearance requires adjustment, as noted in official prescribing information. Caution is also advised when administering the medicine to older adults, due to the greater probability of age-related decline in kidney function.

Functional Restrictions

Due to the potential for somnolence, official regulatory text advises caution regarding activities requiring high mental alertness, such as driving or operating potentially dangerous machinery. Furthermore, caution is advised in patients with predisposing factors for urinary retention. Post-marketing reports also note cases of severe pruritus or urticaria following the cessation of long-term use, representing a time-related safety pattern documented by regulatory authorities.

Advertisements

Overdose and Emergency Response

Rinozine Overdose and when to seek help

Domain Official Regulatory Statement
Documented Manifestations Symptoms are primarily linked to the Central Nervous System (CNS) and include pronounced somnolence, fatigue, confusion, headache, and dizziness. Other effects noted in regulatory documentation include tachycardia (fast heart rate), urinary retention, and mydriasis (pupil dilation).
Population-Specific Notes Overdose in children or infants may initially present with irritability and agitation followed by the onset of drowsiness. This medicine is excreted primarily by the kidney, and caution is noted for patients with renal impairment.
Emergency Actions Regulatory authorities explicitly require to get medical help or contact a Poison Control Center right away for suspected overdose.
Severe Outcome Triggers Immediate use of emergency services is mandated if a person shows signs of collapse, seizure (convulsions), or has trouble breathing.

Management Notes The official position confirms that no known specific antidote exists for the active ingredient. Treatment for overdose is defined as symptomatic and supportive, although gastric lavage may be considered if performed shortly after ingestion. The substance is also not effectively removed by dialysis. These statements define the mandatory emergency protocols and the limits of pharmacological intervention for overdose scenarios, strictly aligning with government regulatory guidance.

Advertisements

Therapeutic Uses of Rinozine

Main Uses and Therapeutic Intent

Rinozine is a multi-component topical preparation designed to manage symptoms associated with inflammatory and infectious conditions of the nasal mucosa. Its primary application is the supportive treatment of dry, irritated, or damaged nasal passages, particularly when these conditions are complicated by minor bacterial involvement.

The formulation is commonly used to address:

  • Chronic and Acute Rhinitis: Assisting in the management of inflammation within the nasal cavity.
  • Bacterial Colonization: Providing localized antiseptic action to help limit the growth of certain microorganisms on the mucosal surface.
  • Mucosal Dryness: Alleviating discomfort caused by the formation of crusts or the drying of the nasal lining due to environmental factors or prolonged illness.

Benefits for Nasal Health

The therapeutic benefit of Rinozine stems from its ability to combine antiseptic properties with a protective vehicle. This dual approach supports the physiological functions of the nose in several ways:

Protection of the Nasal Lining

The ointment base acts as a physical barrier, coating the sensitive nasal mucosa. This helps to prevent further irritation from external factors such as dry air, dust, or pollutants, allowing the underlying tissue a better environment for natural recovery.

Antiseptic Action

By incorporating active agents with antimicrobial properties, the preparation helps to reduce the presence of pathogens in the nasal vestibule. This is particularly beneficial in preventing the worsening of minor infections and reducing the likelihood of recurring crusting associated with bacterial activity.

Symptomatic Relief of Irritation

Patients experiencing soreness, itching, or a burning sensation due to mucosal erosion find relief through the emollient effect of the preparation. By softening existing crusts and preventing the formation of new ones, it facilitates easier breathing and improves overall nasal comfort.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Rinozine?

Rinozine (Cetirizine Hydrochloride) eligibility is strictly defined by regulatory authorities based on age, physiological state, and existing medical conditions.

Contraindicated and Restricted Populations

Category Regulatory Status
Absolute Contraindication Patients with known hypersensitivity to cetirizine, hydroxyzine, or any piperazine derivatives. Patients with severe renal impairment (creatinine clearance less than 10 mL/min) and those with rare hereditary metabolic disorders (for tablet forms).
Restricted/Conditional Use Patients with moderate renal impairment (CrCl 10 to 49 mL/min) or hepatic impairment require professional assessment. Use with caution is advised for patients with predisposing factors for urinary retention or those at risk of convulsions.
Not Recommended Use is not recommended for women who are breastfeeding as the drug is excreted into breast milk. The tablet form is generally not recommended for children under six years of age.
Pregnancy Eligibility Use should be avoided unless clearly needed and only following medical consultation.

Age-Based Eligibility

Official labeling permits use in adults and adolescents (12 years) and in children (6 to 11 years). Specific liquid formulations may be eligible for use in infants as young as six months for certain indications, such as chronic idiopathic urticaria.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacodynamic and Substance Interactions

Co-administration of Rinozine (Cetirizine Hydrochloride) with alcohol (ethanol) or other Central Nervous System (CNS) depressants may cause a significant additive reduction in alertness and increased impairment of CNS performance. This is classified as a pharmacodynamic interaction, leading to caution regarding concurrent use. Combining Rinozine with other antihistamines is documented to increase the overall risk of side effects and potential overdosage.

Pharmacokinetic and Clearance Alterations

Specific drug interactions are documented to alter the clearance of Rinozine. Co-administration with Theophylline (400 mg once daily) resulted in a 16% decrease in the clearance of cetirizine. The disposition of Theophylline was not altered in this study. No clinically significant pharmacokinetic interactions were observed in regulatory studies conducted with Azithromycin, Erythromycin, Ketoconazole, or Pseudoephedrine. Cetirizine is classified as a P-glycoprotein (P-gp) substrate.

Food and Population Considerations

The presence of food does not affect the total extent of absorption (AUC), but it decreases the peak plasma concentration (Cmax) by 23% and delays the rate of absorption. Furthermore, in patients with hepatic impairment or renal disease, the clearance of Rinozine is reduced, which increases systemic exposure and potentially amplifies the effects of co-administered CNS depressants.

Advertisements

Mechanism of Action

Rinozine is a small molecule pharmacologic agent that acts as a highly selective inhibitor. Its mechanism of action begins with direct, concentration-dependent binding to the cellular FADD-like IL-1β-converting enzyme-inhibitory protein (c-FLIP) in the intracellular domain. This targeted molecular interaction prevents the formation of the death-inducing signaling complex (DISC) assembly, which is essential for initiating apoptosis. Consequently, Rinozine modulates the intrinsic signaling cascade by blocking the activation and subsequent cleavage of pro-caspase-8. The inhibition of this upstream event mitigates a major pro-inflammatory pathway. By suppressing the activity of the c-FLIP/caspase-8 axis, the drug alters the molecular signaling balance that would otherwise drive excessive tissue degradation. This intracellular consequence results in the modulation of the overall cellular inflammatory environment, evidenced by a reduction in specific downstream inflammatory markers. The pharmacodynamic focus is strictly on these molecular and cellular processes.

Advertisements

Dosage and Administration Information

How Rinozine (Cetirizine Hydrochloride) Is Used

The usage of Rinozine is defined by specific administration routes and precise dosage regimens.

Official Routes and Forms

Rinozine is primarily used via the oral route as tablets, capsules, or oral solutions for managing seasonal and perennial symptoms. A separate intravenous (IV) injectable form is also available for administration in specialized settings to treat acute urticaria. Oral forms are generally taken once every 24 hours, which is the standard frequency established across all approved indications.


Standard Dosing and Administration Context

For most adults, the standard oral dosage is 10 mg once daily, though a starting dose of 5 mg once daily may be used depending on individual response. The medicine may be taken with or without food, as food can delay the rate of absorption but does not significantly alter the overall amount of the drug absorbed. When administered intravenously for acute conditions, the 10 mg dose must be given slowly, specifically as an intravenous push over 1 to 2 minutes.


Population-Specific Adjustments

Dose adjustments are required based on a patient's kidney function, as the drug is mainly cleared by the kidneys. For adults with moderate to severe renal impairment, the dose or frequency is reduced (e.g., to 5 mg once daily or 5 mg once every two days) to prevent accumulation. For pediatric patients, children 6 to 11 years typically receive a maximum of 10 mg daily, and children 2 to 5 years have a maximum dose of 5 mg daily. If a dose is missed, it is advised to take it as soon as possible, but not taking a double dose to compensate.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rinozine

This section provides a descriptive overview of the research structure for Rinozine (cetirizine hydrochloride) to help contextualize the available evidence. The information below describes what research was conducted and what patterns were observed; it is not a guide for use or a statement on individual patient outcomes.


Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

The evidence base for Rinozine in allergic rhinitis—a condition characterized by fluctuating or episodic manifestations—was studied in short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies monitored patient-reported outcomes describing perceived discomfort using standardized tools like the Total Symptom Score (TSS) and broader Quality of Life (QoL) questionnaires.

Research describes patterns related to symptom evolution that was observed in some studies that included other antihistamine agents as comparators. Research measured changes during the study period in outcomes related to physical discomfort. Subgroup findings are uncertain for specific populations, such as adults aged 65 years and older, due to their limited inclusion in the initial trials.


Evidence for Use in Chronic Urticaria (Hives)

Rinozine was studied for its use in chronic urticaria, a condition presenting with cycles of stability and flare-ups. The research utilized short-term RCTs conducted during periods of increased symptom activity. The core measurements were patient-reported outcomes describing perceived discomfort related to pruritus (itching) and investigator assessments of skin lesions, which are outcomes related to physical discomfort. This research focused on both adult and pediatric populations.

Studies report how symptoms evolved in the observed populations, and they monitored changes in the severity of itching and the physical appearance of the hives across observation periods. Follow-up durations were limited in the pivotal trials. The research provides limited information for long-term outcomes and little insight into higher-than-standard dosing patterns that studies explored.


Key Limitations and Areas of Research Uncertainty

Key limitations cited in the literature include that evidence quality varies across studies due to differences in design and patient reporting methods. Comparative evidence is limited for some head-to-head comparisons against other treatments. Sample sizes were modest in specific subgroup analyses, such as those related to acute urticaria dose comparisons. Long-term effects are not fully established, as the impact of continuous use over years is not fully established by controlled trials.

Key Studies & References

  1. Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis
  2. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Rinozine (FAQ)

Q: What happens if I stop taking Rinozine suddenly?

A: Regulatory authorities have noted that stopping Rinozine after long-term, daily use (typically a few months or more) may rarely result in a condition called severe itching (pruritus). Official safety warnings clarify that this rare adverse reaction is a time-related safety pattern, and regulatory documents clarify that it is not viewed as a sign of drug dependence.


Q: Is Rinozine available without a prescription?

A: Rinozine (cetirizine) is widely available over-the-counter (OTC) in its standard formulations and strengths. While it can be bought without a prescription, it is sometimes obtained with a prescription, often for specific insurance coverage needs.


Q: Why are there specific warnings about using Rinozine with grapefruit?

A: While the presence of food in general is noted to delay the rate of absorption of the medicine, official regulatory documents for Rinozine (cetirizine) do not typically list a specific, clinically significant interaction with grapefruit or grapefruit juice.


Q: Does Rinozine have any known interactions with common painkillers like ibuprofen?

A: Official regulatory interaction studies regarding Rinozine (cetirizine) do not generally report a clinically significant interaction with common painkillers such as ibuprofen. Regulatory documents describe other interactions, such as with Central Nervous System (CNS) depressants, in the Interactions section.


Q: Can Rinozine affect my blood pressure?

A: Rinozine (cetirizine) used as a single ingredient is generally not associated with changes in blood pressure in official regulatory documents. Caution is advised regarding combination products that contain decongestants, as these ingredients can be associated with blood pressure effects.


Q: Is Rinozine addictive?

A: No, Rinozine is not classified as an addictive substance. Although regulatory authorities have issued a warning about the rare occurrence of severe itching when stopping long-term use, regulatory documents clarify that this reaction is not considered a sign of addiction or dependence.


Q: Does Rinozine lose its effectiveness over time (tolerance)?

A: Official product labeling does not typically mention a loss of effectiveness, also known as tachyphylaxis or tolerance, with Rinozine. It is commonly used for long-term management of chronic conditions, indicating sustained efficacy in these populations.


Q: Is it required to take Rinozine every day for it to work?

A: Rinozine is typically dosed once every 24 hours for its approved uses. The necessity of continuous daily use depends on the specific condition being managed (e.g., chronic versus episodic symptoms).


Q: Is Rinozine a steroid?

A: No, Rinozine is not a steroid. Regulatory documents classify Rinozine as a selective H1-receptor antagonist, which is a type of second-generation antihistamine used to block the effects of histamine.


Q: Can Rinozine interact with dietary supplements like St. John's Wort?

A: The official product labeling lists no known clinically significant pharmacokinetic interactions between Rinozine (cetirizine) and common herbal or dietary supplements such as St. John's Wort. Official guidance emphasizes the importance of sharing a complete list of all supplements and medications with a healthcare provider.


Q: Is Rinozine considered a high-risk medication during pregnancy?

A: Official regulatory guidance advises that Rinozine use should be avoided during pregnancy unless clearly needed and only following a professional consultation. While older references may have categorized it based on available data, the updated labeling emphasizes a careful risk-benefit discussion.


Q: Does Rinozine cause weight gain?

A: Weight gain is not listed among the common or frequent adverse reactions in official product labeling. Any concerns regarding changes in body weight may be discussed with a healthcare professional.


Q: How long does the effect of one Rinozine dose usually last?

A: Studies and official information indicate that the effects of Rinozine typically begin within 20 to 60 minutes after administration. The duration of its primary action is designed to persist for at least 24 hours, which is why it is dosed once daily.


Q: Do people typically take Rinozine in the morning or evening?

A: Rinozine is approved to be taken once daily and may be taken at any time, with or without food. Because somnolence (drowsiness) is a documented common side effect, some people choose to take it in the evening to help minimize potential daytime drowsiness, but no specific time is mandated.


Q: Are there any food restrictions when taking Rinozine?

A: The official product labeling states that Rinozine may be taken with or without food. While having food in the stomach can delay the rate at which the medicine is absorbed, it does not significantly change the overall amount of the drug that enters the body.


Q: How is Rinozine different from its predecessor drug?

A: Rinozine (cetirizine) is an active metabolite of the older antihistamine drug Hydroxyzine. Rinozine is designed to have the same effective antihistamine action while causing significantly less sedation and fewer anticholinergic effects. This difference stems from Rinozine's poor ability to penetrate the central nervous system barrier.


Q: Does Rinozine interact with oral contraceptives?

A: Specific regulatory studies have not reported a clinically significant drug interaction between Rinozine (cetirizine) and oral contraceptives. Official guidance emphasizes the importance of sharing a complete list of all medications, including birth control, with a healthcare provider.


Q: Are there any rare side effects of Rinozine that are often discussed online?

A: A post-marketing safety pattern that has been discussed is the rare occurrence of severe itching (pruritus) upon discontinuing Rinozine after long-term use. This reaction is documented in updated official product labeling.


Q: Can Rinozine be crushed or chewed?

A: The tablets and capsules are typically designed and intended by the manufacturer to be swallowed whole. Liquid forms, such as the syrup or oral solution, are available and generally used for patients who have difficulty swallowing tablets.


Q: Does Rinozine affect liver function?

A: Rinozine has been associated with rare instances of abnormal hepatic function (such as elevated liver enzymes) in official adverse reaction reports. Due to reduced drug clearance, dose adjustments are typically required for patients with pre-existing hepatic impairment.


Q: What is the maximum duration of use recommended in official labeling?

A: There is no universally stated maximum duration for Rinozine use in official labeling. It is often prescribed for chronic conditions, but regulatory reports note that the long-term effects of continuous use over years are not fully established by controlled clinical trials.


Q: Does taking Rinozine require any special monitoring or blood tests?

A: Routine blood tests are not typically required for healthy patients taking Rinozine. However, for patients with known kidney (renal) or liver (hepatic) impairment, medical monitoring may be advised due to the drug’s reduced clearance in these groups.


Q: Is the effect of Rinozine immediate, or does it build up over time?

A: Rinozine is considered to be a fast-acting medication. Official sources indicate that the onset of action, or when the first effects are typically felt, occurs within 20 to 60 minutes of taking a dose.


Q: What is Rinozine's safety profile compared to older drugs in the same class?

A: Rinozine is a second-generation antihistamine, a class that is clinically recognized for having a minimized potential for sedation compared to earlier first-generation drugs. This improved safety profile is a key distinguishing feature noted in regulatory documents.


Q: Do official sources mention Rinozine being used for conditions other than allergies?

A: Official product labeling specifies approved uses for seasonal and perennial allergic rhinitis (forms of allergies). It is also approved for the treatment of chronic urticaria (hives).


Q: What is the main difference between Rinozine and over-the-counter allergy pills?

A: Rinozine is itself available over-the-counter and is classified as a second-generation antihistamine. This class of medicine is known for being highly selective in blocking the effects of histamine, often resulting in less sedation than some older or first-generation antihistamines.


Q: Can Rinozine be used for cold symptoms, even if it's mainly for allergies?

A: Official regulatory texts confirm that Rinozine is approved to treat symptoms related to allergic conditions, specifically seasonal and perennial allergic rhinitis, and chronic urticaria. Its approved indications do not include the treatment of general cold symptoms.


Q: How quickly should I expect Rinozine to start working?

A: Studies and official information indicate that the onset of action typically occurs within 20 to 60 minutes after taking a dose. This time frame represents the general expectation for when the effects of Rinozine are first felt.


Q: Can Rinozine be taken while breastfeeding?

A: Official labeling advises that use of Rinozine is not recommended for women who are breastfeeding because the drug is known to be excreted into breast milk. This statement is based on potential safety concerns for the infant.


Q: Is Rinozine appropriate for children under the age of 12?

A: Official labeling permits the use of Rinozine for children, with specific dosage guidelines provided for pediatric patients. Eligibility ranges from adolescents (12 years and older) down to children 6 to 11 years of age, and even infants as young as six months for certain liquid formulations and indications.


Q: What evidence exists about Rinozine's use in chronic conditions?

A: Rinozine was specifically studied in randomized controlled trials for use in chronic urticaria (hives), which is a chronic condition. While this research supports its use in these persistent conditions, regulatory reports also note that information on the long-term effects of continuous use over years is limited.


Q: Why is Rinozine restricted for people with certain heart conditions?

A: Official regulatory documents do not list specific heart conditions as a contraindication for Rinozine. However, restricted or conditional use is advised for people with predisposing factors for urinary retention and those at risk of convulsions.


Q: Why do official documents describe Rinozine as a 'selective modulator'?

A: Official documents define Rinozine as a selective H1-receptor antagonist. The drug's mechanism of action involves a targeted molecular interaction that modulates or alters the overall cellular inflammatory environment, which is why it may be broadly referred to as a 'selective modulator' of the allergic response.

Advertisements

How should Rinozine be stored and disposed of?

How to Store and Dispose of Rinozine

Official regulatory guidelines strictly define the conditions under which Rinozine must be stored and disposed of to maintain its effectiveness and ensure safety.


Storage Requirements

Element Official Regulatory Statement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Handling Avoid storage outside of the allowed temperature excursion range left(15 C to 30 C
ight).
Child Safety Keep Rinozine out of the sight and reach of children and pets.

Disposal Requirements

Element Official Regulatory Statement
Method Utilize a drug take-back program or follow the household trash protocol.
Environmental Do NOT dispose of the medication by flushing it down a toilet or pouring it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rinozine found in:

A-Z Index: